Lamictal 5mg chewable/dispersible tablets
- Name:
Lamictal 5mg chewable/dispersible tablets
- Company:
GlaxoSmithKline (Ireland) Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 18/01/21
(Click to Download)Click on this link to Download PDF directly
GlaxoSmithKline (Ireland) Ltd
 Ltd.jpg)
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 18 January 2021 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.4: Addition of photosensitivity reaction warning
Section 4.8: Addition of photosensitivity reaction undesirable effect to the skin and subcutaneous tissue disorders under frequency uncommon
Updated on 18 January 2021 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 18 January 2021 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 9 December 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.4. Update the wording on hypersensitivity syndrome.
Section 4.8 Removal of duplicate Hypersensitivity syndrome symptoms from the adverse event table
Section 4.8 Minor update – aseptic meningitis under nervous system disorders was moved from the bottom to the middle paragraph.
Section 4.8 Addition of the ADR Tubulointerstitial nephritis (TIN) that may occur in association with uveitis and involvement of the kidney as part of DRESS.
Section 4.8 Update to description of selected adverse reactions: Haematological abnormalities and lymphadenopathy and Rash.
Section 4.8 removal of duplicate statement regarding rash reported as part of hypersensitivity syndrome.
Section 4.8 Update to reporting of side effects details.
Updated on 9 December 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 13 March 2020 PIL
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 6 - date of revision
Updated on 13 March 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.4 - Addition of warnings for sodium content
Updated on 5 November 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 5 November 2018 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
To update SmPC Section 4.4, 4.6, 4.8, PIL Section 2 & Section 4 in line with CMDh adopted PRAC recommendation. Inclusion of Brugada syndrome and haemophagocytic lymphohistiocytosis in take special care. Also a note to woman that are breastfeeding to observe if any symptoms are observed in the baby.
Updated on 13 July 2018 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
- Update to SmPC Section 4.5 - Interaction with other medicinal products and other forms of interaction – Update wording on Lamictal and Locosomide/Perampanel interaction in the SmPC.
- Update to SmPC Section 4.6 - Pregnancy and lactation – typographical mistake, removal of the word ‘therefore’
Updated on 26 February 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 26 February 2018 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 March 2017 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
6.3 Shelf life - bottle pack updated to 3 years
Updated on 14 November 2016 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
We are updating the same SPC due to typos found in Section 6.3 and Section 6.5 - no other changes were made.
Updated on 3 November 2016 SPC
Reasons for updating
- New individual SPC (was previously included in combined SPC)
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.5 Interaction with other medicinal products and other forms of interaction - Update wording on OCT-2 inhibition in the SMPC.
Please note that the combined SPC for Lamictal chewable/dispersible tablets will no longer be used. The SPC for Lamictal chewable/dispersible tablets will now be individual SPC documents for each strength - SPC for 2mg, SPC for 5mg, SPC for 25mg, SPC for 50mg, SPC for 100mg and SPC for 200mg (6 individual SPCs in total).
The history of the Combined Lamictal chewable/dispersible tablet SPC is attached to the Lamictal chewable/dispersible 200mg Tablets, so the trail of changes remains intact for future perusal. The SPC for 2mg, SPC for 5mg, SPC for 25mg, SPC for 50mg, and SPC for 100mg will be added to Medicines.IE as 'new' documents.
Updated on 14 April 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 14 April 2016 PIL
Reasons for updating
- Change to instructions about missed dose
- Change to side-effects
- Change to information about pregnancy or lactation
- Change to date of revision
- Change to improve clarity and readability
Updated on 18 January 2016 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
- Change to improve clarity and readability
Updated on 15 July 2015 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
Updated on 14 May 2015 PIL
Reasons for updating
- Change to date of revision
- Introduction of new pack/pack size
Updated on 3 March 2015 PIL
Reasons for updating
- Change to date of revision
- Change to side-effects
Updated on 22 October 2014 PIL
Reasons for updating
- Change of trade or active ingredient name
- Change to warnings or special precautions for use
- Change to side-effects
- Change to further information section
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 15 May 2014 PIL
Reasons for updating
- Change of manufacturer
- Change to date of revision
Updated on 22 January 2014 PIL
Reasons for updating
- Change to instructions about overdose
Updated on 24 September 2013 PIL
Reasons for updating
- Change of manufacturer
Updated on 12 September 2012 PIL
Reasons for updating
- Change to side-effects
Updated on 6 December 2011 PIL
Reasons for updating
- Change of contraindications
Updated on 13 December 2010 PIL
Reasons for updating
- Change to drug interactions
- Change to dosage and administration
Updated on 26 January 2010 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to drug interactions
- Change to dosage and administration
- Change to side-effects
Updated on 27 November 2008 PIL
Reasons for updating
- Change due to harmonisation of patient information leaflet
Updated on 8 July 2008 PIL
Reasons for updating
- Change to name of manufacturer
Updated on 11 April 2007 PIL
Reasons for updating
- Change of manufacturer
Updated on 15 November 2006 PIL
Reasons for updating
- Change to warnings or special precautions for use
Updated on 8 June 2006 PIL
Reasons for updating
- Change to warnings or special precautions for use
Updated on 17 January 2006 PIL
Reasons for updating
- Improved electronic presentation
Updated on 9 January 2006 PIL
Reasons for updating
- Improved electronic presentation
Updated on 26 August 2005 PIL
Reasons for updating
- New PIL for medicines.ie